Literature DB >> 15695976

Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST).

Catherine M Viscoli1, Lawrence M Brass, Walter N Kernan, Philip M Sarrel, Samy Suissa, Ralph I Horwitz.   

Abstract

OBJECTIVE: This study was undertaken to assess whether estrogen therapy (ET) reduces the risk of cognitive decline in women with cerebrovascular disease. STUDY
DESIGN: We conducted a randomized, double-blind trial of estradiol 17beta versus placebo for secondary stroke prevention in 664 postmenopausal women with a recent stroke or transient ischemic attack. The Mini-Mental State Examination (MMSE) and 5 domain measures were obtained at baseline and exit.
RESULTS: Among 461 women withdrawn alive without stroke, ET did not have a significant effect on cognitive measures after an average of 3 years (relative risk of MMSE decline: 0.74, 95% CI, 0.49-1.13). In women with normal MMSE at entry, estrogen was associated with less decline (relative risk, 0.46, 95% CI, 0.24-0.87).
CONCLUSION: In this study, estradiol did not have significant effects on cognitive measures. However, in women with normal function at baseline, there may be a benefit for ET in reducing the risk for cognitive decline.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695976     DOI: 10.1016/j.ajog.2004.08.017

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  29 in total

1.  Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition.

Authors:  Pauline M Maki; Ellen W Freeman; Gail A Greendale; Victor W Henderson; Paul A Newhouse; Peter J Schmidt; Nelda F Scott; Carol A Shively; Claudio N Soares
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

Review 2.  Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for age-related memory decline.

Authors:  Karyn M Frick
Journal:  Behav Neurosci       Date:  2012-02       Impact factor: 1.912

Review 3.  Hormone therapy and cognitive function.

Authors:  Pauline M Maki; Erin Sundermann
Journal:  Hum Reprod Update       Date:  2009-05-25       Impact factor: 15.610

Review 4.  Cognitive changes after menopause: influence of estrogen.

Authors:  Victor W Henderson
Journal:  Clin Obstet Gynecol       Date:  2008-09       Impact factor: 2.190

Review 5.  Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.

Authors:  P M Maki; V W Henderson
Journal:  Climacteric       Date:  2012-06       Impact factor: 3.005

Review 6.  Effects of the Menstrual Cycle on Neurological Disorders.

Authors:  Hannah J Roeder; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-10       Impact factor: 5.081

7.  Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.

Authors:  Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel
Journal:  Menopause       Date:  2008 Jul-Aug       Impact factor: 2.953

Review 8.  Aging, estrogens, and episodic memory in women.

Authors:  Victor W Henderson
Journal:  Cogn Behav Neurol       Date:  2009-12       Impact factor: 1.600

9.  Aging and Loss of Circulating 17β-Estradiol Alters the Alternative Splicing of ERβ in the Female Rat Brain.

Authors:  Cody L Shults; Elena Pinceti; Yathindar S Rao; Toni R Pak
Journal:  Endocrinology       Date:  2015-08-21       Impact factor: 4.736

10.  Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study".

Authors:  Sanjay Asthana; Roberta Diaz Brinton; Victor W Henderson; Bruce S McEwen; John H Morrison; Peter J Schmidt
Journal:  Age (Dordr)       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.